Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Myeloid Therapeutics
Memorial Sloan Kettering Cancer Center
Toray Industries, Inc
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Exelixis
Compugen Ltd
Eli Lilly and Company
Astellas Pharma Inc
Molecular Templates, Inc.
National University Hospital, Singapore
Fate Therapeutics
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Five Prime Therapeutics, Inc.
AbbVie